Localized Prostate Cancer COE

Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp

Details
The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...

Racial and Ethnic Disparity in the Use of Prostate MRI - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen review the publication titled "Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test." The study evaluated the association between race and ethnicity and the mean time between prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Among men with elevated PSA results...

Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain

Details
In this discussion, Paul Nguyen is joined by co-authors Bhav Jain and Edward Christopher Dee to discuss a Prostate Cancer and Prostatic Diseases publication "Racial Disparities in Treatment Delay Among Younger Men (<55 years of age) with Prostate Cancer". In this presentation and discussion, Bhav Jain shares that using the United States National Cancer Database (2004-2017), the authors' multivaria...

Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...

Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks

Details
Alicia Morgans and Michael Brooks discuss a recent manuscript entitled, “Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-years After Radical Prostatectomy”. Dr. Brooks goes into depth on how adverse pathology correlates with long-term prostate cancer outcomes. They also discuss active surveillance for low-risk patients and how to stratify th...

Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein

Details
Alicia Morgans and Eric Klein discuss two papers that involve a unique cohort of patients with early-stage prostate cancer. Dr. Klein details the use of the Oncotype GPS score to stratify patients and determine who is safe for active surveillance. They also discuss how to use MRI histology, adverse pathology, and genomic profiling systems together. They discuss advising clinicians on how to start...

AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt

Details
In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...

Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski

Details
Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI. This phase III randomized NRG/RTOG 0126 trial provides the first validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. Dr. Spratt provides the background on the rationale for the NRG/RTOG 0126 and the results from the RTOG 0126 trial. They discus...

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

Details
Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...

The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.

Details
Daniel Spratt and Randy Vince discuss the impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer. This conversation starts off with a background on Decipher Biopsy testing and how it is used for men with prostate cancer. This then transitions into a discussion on the controls and background of how the study was set up. Dr. Vince then discusses some of the main findings...
email news signup